Cliff Asness's ALNY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 744.0K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $336.01 M, representing 0.22% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ALNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 555.8K shares. Largest reduction occurred in Q2 2025, reducing 640.1K shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +35,495 | Add 0.00% | 35,494 | $18.26 |
| Q2 2013 | +44,495 | Add 0.00% | 44,494 | $31.02 |
| Q3 2013 | -211 | Reduce 0.47% | 44,283 | $64.02 |
| Q4 2013 | -20,878 | Reduce 47.15% | 23,405 | $64.35 |
| Q1 2014 | -2,200 | Reduce 9.40% | 21,205 | $67.15 |
| Q2 2014 | +6,800 | Add 32.07% | 28,005 | $63.17 |
| Q3 2014 | +2,264 | Add 8.08% | 30,269 | $78.10 |
| Q4 2014 | -11,900 | Reduce 39.31% | 18,369 | $97.01 |
| Q1 2015 | +28,979 | Add 157.76% | 47,348 | $104.42 |
| Q2 2015 | +34,764 | Add 73.42% | 82,112 | $119.87 |
| Q3 2015 | +71,679 | Add 87.29% | 153,791 | $80.36 |
| Q4 2015 | +62,887 | Add 40.89% | 216,678 | $94.14 |
| Q1 2016 | -212,939 | Reduce 98.27% | 3,739 | $62.85 |
| Q2 2016 | -3,739 | Sold Out | 3,739 | $0.00 |
| Q4 2016 | +27,669 | New Buy | 27,669 | $37.44 |
| Q1 2017 | -27,669 | Sold Out | 27,669 | $0.00 |
| Q4 2017 | +6,545 | New Buy | 6,545 | $127.12 |
| Q1 2018 | +7,676 | Add 117.28% | 14,221 | $119.12 |
| Q2 2018 | -334 | Reduce 2.35% | 13,887 | $98.51 |
| Q3 2018 | -4,249 | Reduce 30.60% | 9,638 | $87.57 |
| Q4 2018 | -9,638 | Sold Out | 9,638 | $0.00 |
| Q1 2019 | +2,367 | New Buy | 2,367 | $93.37 |
| Q2 2019 | -2,367 | Sold Out | 2,367 | $0.00 |
| Q1 2020 | +46,218 | New Buy | 46,218 | $108.85 |
| Q2 2020 | +48,963 | Add 105.94% | 95,181 | $148.11 |
| Q3 2020 | -23,400 | Reduce 24.58% | 71,781 | $144.17 |
| Q4 2020 | -32,134 | Reduce 44.77% | 39,647 | $128.51 |
| Q1 2021 | -37,733 | Reduce 95.17% | 1,914 | $140.54 |
| Q2 2021 | -1,914 | Sold Out | 1,914 | $0.00 |
| Q4 2021 | +2,124 | New Buy | 2,124 | $169.49 |
| Q1 2022 | +9,123 | Add 429.52% | 11,247 | $163.33 |
| Q2 2022 | -5,233 | Reduce 46.53% | 6,014 | $143.83 |
| Q3 2022 | +5,754 | Add 95.68% | 11,768 | $200.12 |
| Q4 2022 | -11,768 | Sold Out | 11,768 | $0.00 |
| Q1 2023 | +6,107 | New Buy | 6,107 | $198.29 |
| Q2 2023 | -373 | Reduce 6.11% | 5,734 | $189.94 |
| Q3 2023 | +3,726 | Add 64.98% | 9,460 | $175.81 |
| Q4 2023 | +4,560 | Add 48.20% | 14,020 | $191.41 |
| Q1 2024 | +127,117 | Add 906.68% | 141,137 | $149.45 |
| Q2 2024 | +130,482 | Add 92.45% | 271,619 | $242.48 |
| Q3 2024 | +234,035 | Add 86.16% | 505,654 | $274.80 |
| Q4 2024 | +307,702 | Add 60.85% | 813,356 | $235.31 |
| Q1 2025 | +14,988 | Add 1.84% | 828,344 | $262.00 |
| Q2 2025 | -640,095 | Reduce 77.27% | 188,249 | $325.55 |
| Q3 2025 | +555,759 | Add 295.23% | 744,008 | $451.62 |
Cliff Asness's Alnylam Pharmaceuticals Investment FAQs
Cliff Asness first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q4 2012, acquiring 35,494 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Alnylam Pharmaceuticals, Inc. (ALNY) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2025, adding 744,008 shares worth $336.01 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 744,008 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $336.01 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.22% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 828,344 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.